(Q39816187)

14 September 2017

Investigation of Pharmacodynamic and Pharmacokinetic Interactions Between Rivaroxaban and Enoxaparin in Healthy Male Subjects (English)

1 reference

14 September 2017

1 reference

1 reference

Dagmar Kubitza

1

1 reference

14 September 2017

Michael Becka

series ordinal

2

1 reference

14 September 2017

Stephan Schwers

series ordinal

3

1 reference

14 September 2017

Barbara Voith

series ordinal

4

1 reference

14 September 2017

15 May 2013

1 reference

Clinical pharmacology in drug development

14 September 2017

1 reference

14 September 2017

2

1 reference

14 September 2017

3

1 reference

14 September 2017

270-277

1 reference

Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

14 September 2017

1 reference

Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

21 January 2018

1 reference

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor

21 January 2018

1 reference

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects

21 January 2018

1 reference

Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty

21 January 2018

1 reference

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial

21 January 2018

1 reference

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty

21 January 2018

1 reference

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial

21 January 2018

1 reference

Determination of rivaroxaban--a novel, oral, direct Factor Xa inhibitor--in human plasma by high-performance liquid chromatography-tandem mass spectrometry

21 January 2018

1 reference

Enoxaparin. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders

21 January 2018

2 references

21 January 2018

7 January 2021

Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice

1 reference

Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement

21 January 2018

1 reference

Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects

21 January 2018

1 reference

7 January 2021

Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls

1 reference

7 January 2021

Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement

1 reference

7 January 2021

Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies.

1 reference

7 January 2021

Identifiers

DOI

10.1002/CPDD.26

1 reference

14 September 2017

1 reference